drugset / Trial / NCT03092726

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

NCT03092726

Phase 2 Completed 183 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability. This study also assessed the treatment differences in physical function as well the improvements in overall subject status (e.g., fibromyalgia symptoms, global functioning) of ASP8062 relative to placebo.

Timeline

Start
2017-05-08
Primary completion
2018-03-06
Completion
2018-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP8062 Unknown 30 mg Oral

Indications